Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.36 |
| ▸ | CCND1 | P24385 | 1/20 | 0.36 |
| ▸ | CCNC | P24863 | 1/20 | 0.36 |
| ▸ | CDK8 | P49336 | 1/20 | 0.36 |
| ▸ | CDK7 | P50613 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
| ▸ | CCNH | P51946 | 1/20 | 0.36 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.36 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | IKBKB | O14920 | 3/20 | 0.35 |
| ▸ | CHUK | O15111 | 3/20 | 0.35 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NNMT | P40261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrrole SCHEMBL12467466 | 0.91 | PDPK1 (0.38) | PDPK1RIPK1PIM1LMNAMAPK1 | |
| SCHEMBL4308970 | 0.84 | RIPK1 (0.31) | PDPK1RIPK1MAPK1DYRK1A | |
| SCHEMBL4102491 | 0.81 | KDM4E (0.48) | LMNAALDH1A1 | |
| SCHEMBL4112718 | 0.80 | P2RX7 (0.49) | MAPK1DYRK1AALDH1A1 | |
| SCHEMBL4309792 | 0.80 | JAK3 (0.33) | GSK3B | |
| SCHEMBL7052922 | 0.79 | KDM4E (0.32) | DYRK1A | |
| SCHEMBL10424836 | 0.78 | PDPK1 (0.38) | PDPK1RIPK1PIM1LMNAMAPK1 | |
| SCHEMBL19463620 | 0.76 | PIM1 (0.43) | PDPK1RIPK1PIM1LMNAMAPK1 | |
| SCHEMBL2785730 | 0.76 | MAPK1 (0.42) | MAPK1CDK8ALDH1A1 | |
| Cytosine SCHEMBL27595867 | 0.75 | TSHR (0.40) | PDPK1RIPK1MAPK1CCNT1CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2592070-B1 | Tetrazole-substituted arylamides | HOFFMANN LA ROCHE (CH) | 2016-08-31 | — | — | EP | claimed |
| EP-1937652-B1 | PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS | AVENTIS PHARMA INC (US) | 2014-07-30 | — | — | EP | claimed |
| EP-2592070-A2 | Tetrazole-substituted arylamides | F. Hoffmann-La Roche AG (CH) | 2013-05-15 | — | — | EP | claimed |
| US-8202863-B2 | 2-Phenyl-pyrimidine-5-carboxylic acid benzylamide; to treat allergic and/or inflammatory disorders, particularly disorders such as allergic rhinitis, asthma and/or chronic obstructive pulmonary disease | AVENTIS PHARMACEUTICALS INC. (US) | 2012-06-19 | — | — | US | claimed |
| EP-1991543-A1 | 4-PHENYL-THIAZOLE-5-CARBOXYLIC ACIDS AND 4-PHENYL-THIAZOLE-5-CARBOXYLIC ACID AMIDES AS PLK1 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2008-11-19 | — | — | EP | claimed |
| US-20080227782-A1 | PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2008-09-18 | — | — | US | claimed |
| EP-1937652-A1 | PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2008-07-02 | — | — | EP | claimed |
| WO-2007096315-A1 | 4-PHENYL-THIAZOLE-5-CARBOXYLIC ACIDS AND 4-PHENYL-THIAZOLE-5-CARBOXYLIC ACID AMIDES AS PLK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-30 | — | — | WO | claimed |
| US-20070203210-A1 | Thiazolyl-benzimidazoles | BOYLAN JOHN FREDERICK | 2007-08-30 | — | — | US | claimed |
| WO-2007041634-A1 | PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-04-12 | — | — | WO | claimed |
| US-20220041606-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | UNIV VANDERBILT (US) | 2022-02-10 | — | — | US | disclosed |
| US-10201525-B2 | Tetrazole-substituted arylamides as PX2 and PX2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2019-02-12 | — | — | US | disclosed |
| US-20170143672-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES AS PX2 AND PX2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2017-05-25 | — | — | US | disclosed |
| EP-2847174-B1 | PYRIMIDINONE CARBOXAMIDES AS INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL MYERS SQUIBB CO (US) | 2017-05-17 | — | — | EP | disclosed |
| US-9593128-B2 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | HOFFMANN-LA ROCHE INC. (US) | 2017-03-14 | — | — | US | disclosed |
| WO-2007096315-A1 | 4-PHENYL-THIAZOLE-5-CARBOXYLIC ACIDS AND 4-PHENYL-THIAZOLE-5-CARBOXYLIC ACID AMIDES AS PLK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-30 | — | — | WO | disclosed |
| WO-2007041634-A1 | PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-04-12 | — | — | WO | disclosed |
| WO-2003028739-A2 | COMPOSITION FOR PREVENTING OR TREATING HYPERLIPIDEMIA OR HYPERGLYCEMIA COMPRISING A POLYMER OR ITS SALT | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-04-10 | — | — | WO | disclosed |
| WO-2002032974-A2 | POLYMER AND ITS USE FOR THE TREATMENT AND/OR PREVENTION OF HYPERPHOSPHOREMIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-04-25 | — | — | WO | disclosed |
| US-6107301-A | PSYCHOLOGICAL DISORDERS | DUPONT PHARMACEUTICALS COMPANY (US) | 2000-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227782-A1 | PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS | HRH2, HRH1, LTC4S | PDPK1 395/4885RIPK1 3162/4885PIM1 2833/4885 |
| US-20170143672-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES AS PX2 AND PX2/3 ANTAGONISTS | P2RX2, P2RX3, TPX2 | PDPK1 2474/4885RIPK1 2953/4885PIM1 3795/4885 |
| US-20220041606-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | CHRM1, CHRM4, CHRM2 | PDPK1 1231/4885RIPK1 1799/4885PIM1 3747/4885 |
| US-20070203210-A1 | Thiazolyl-benzimidazoles | CYP3A7, CYP2C19, CYP3A5 | PDPK1 3462/4885RIPK1 4731/4885PIM1 287/4885 |
| US-10201525-B2 | Tetrazole-substituted arylamides as PX2 and PX2/3 antagonists | P2RX2, P2RX3, TPX2 | PDPK1 2493/4885RIPK1 3021/4885PIM1 3900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.